Anfield Capital Management’s Rayliant Quantamental China Equity ETF RAYC Stock Holding History

Anfield Capital Management’s Portfolio RAYC Stock Details RAYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-9,487	Closed	-$211K	–	91
2022 Q2	$211K	Sell	9,487 -23,750	-71%	-$487K	0.1%	71
2022 Q1	$746K	Buy	33,237 +150	+0.5%	+$3.52K	0.27%	48
2021 Q4	$842K	Buy	+33,087	New	+$838K	0.29%	49
2021 Q3	–	Sell	-30,311	Closed	-$831K	–	231
2021 Q2	$831K	Buy	+30,311	New	+$812K	0.32%	50

Other funds holding RAYC

Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

PWM

Perigon Wealth Management San Francisco, California $5.51B AUM 24.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Anfield Capital Management's RAYC Position: Q3 2022 in Review

Anfield Capital Management sold out of Rayliant Quantamental China Equity ETF (RAYC) in Q3 2022, closing a stake of 9,487 shares — an estimated $211K sold.

Anfield Capital Management first reported a position in RAYC in Q2 2021 and held it in 4 quarters. The position peaked at $842K in Q4 2021. 5 funds tracked by Wall St. Rank hold RAYC as of Q3 2022.

Anfield Capital Management reported no remaining Rayliant Quantamental China Equity ETF position as of Q3 2022 after selling out during the quarter.
Anfield Capital Management sold 9,487 Rayliant Quantamental China Equity ETF shares in Q3 2022, an estimated $211K.
Anfield Capital Management first reported a position in Rayliant Quantamental China Equity ETF in Q2 2021 and held it in 4 quarters.
Anfield Capital Management's Rayliant Quantamental China Equity ETF position peaked at $842K in Q4 2021.
5 funds tracked by Wall St. Rank held Rayliant Quantamental China Equity ETF as of Q3 2022.

Based on Anfield Capital Management's 13F filing for Q3 2022, filed 9 Nov 2022.